”South Africa has initiated a landmark clinical trial to evaluate the effectiveness of Multiple Micronutrient Supplementation (MMS) in improving maternal and newborn health outcomes. The study, launched in Johannesburg, aims to replace current iron and folic acid supplements with MMS, potentially transforming antenatal care across the country.”
Maternal nutrition has long been recognized as a cornerstone of public health, particularly in countries grappling with high rates of food insecurity and malnutrition. In South Africa, poor maternal nutrition contributes significantly to complications such as low birth weight, premature births, and increased maternal morbidity. On 29 July 2026, the Department of Health, in collaboration with the Sight and Life Foundation, launched a groundbreaking clinical trial to test the efficacy of Multiple Micronutrient Supplementation (MMS) in improving pregnancy outcomes.
Why MMS Matters
- Current Standard of Care: Pregnant women in South Africa are typically provided with iron and folic acid (IFA) supplements.
- Limitations of IFA: While effective in reducing anemia, IFA does not address broader micronutrient deficiencies.
- MMS Advantage: A single tablet combining essential vitamins and minerals, including iron, folic acid, vitamin A, zinc, and iodine, offering a holistic approach to maternal nutrition.
This trial represents a paradigm shift in antenatal care, moving from a narrow focus on anemia prevention to a comprehensive strategy for maternal and newborn health.
Implementation Strategy
- Clinical Sites: The trial is being conducted at the Wits RHI Shandukani Clinical Research Site, Esselen Clinic, Hillbrow Community Health Centre, and the HSB Hill Solomon Building.
- Target Population: Pregnant women from food-insecure communities, where malnutrition is most prevalent.
- Recruitment: Participants are being enrolled under strict ethical and scientific standards, ensuring transparency and credibility.
Expert Perspectives
- Ms. Zandile Kubeka, Deputy Director: Dietetics, Child and Youth Health, emphasized the importance of strengthening maternal nutrition within South Africa’s public health system.
- Healthcare Providers: Midwives and doctors welcomed the trial as a potential game-changer in reducing maternal and infant mortality.
- Global Context: MMS has already shown promising results in other countries, and South Africa’s trial will contribute valuable local evidence to the global body of research.
Broader Implications
- Policy Impact: If successful, MMS could replace IFA as the standard supplement in antenatal care programs.
- Health Outcomes: Improved maternal nutrition could reduce rates of premature births, low birth weight, and neonatal complications.
- Economic Benefits: Healthier pregnancies reduce healthcare costs associated with complications, while healthier children contribute to long-term productivity.
Challenges Ahead
- Adherence: Ensuring pregnant women consistently take MMS supplements.
- Accessibility: Making MMS affordable and widely available across public health facilities.
- Food Security: Supplements alone cannot solve systemic issues of poverty and food insecurity.
Conclusion
The MMS SA 2025 Clinical Trial marks a decisive step in South Africa’s fight against maternal malnutrition. By integrating MMS into antenatal care, the country could significantly improve pregnancy outcomes, reduce infant mortality, and set a precedent for other nations facing similar challenges. This initiative underscores the importance of nutrition as a foundation for health equity and sustainable development.
